Table 1—

Characteristics of the patient populations at the time of the diagnosis of pulmonary arterial hypertension(PAH) and at the onset of i.v. iloprost therapy

Population under study
Time of diagnosisOnset of i.v. iloprost
Subjects n79
Female/Male59/20 (75/25)
Age yrs47±1348±14
 IPAH62 (78)
 PAH-CTD10 (13)
 PAH-CHD2 (3)
 PoPH5 (6)
Functional NYHA class III/IV61/18 (77/23)24/49 (33/67)#
6-min walk distance m287±112228±114
Pra mmHg10±613±6
pa mmHg57±1261±15
Ppcw mmHg8±68±3
 CO L·min−13.0±1.02.7±0.8
 Cardiac index L·min−1·m−21.7±0.61.5±0.4
 PVR dyn·s·cm−51,533±6241,858±856
Sv,O2 %54±1147±10
  • Data are presented as n (%) or mean±sd, unless otherwise stated. i.v.: intravenous; IPAH: idiopathic PAH; CTD: connective tissue disease; CHD: congenital heart disease; PoPH: portopulmonary hypertension; NYHA: New York Heart Association; Pra: right atrial pressure; pa: mean pulmonary arterial pressure; Ppcw: pulmonary capillary wedge pressure; CO: cardiac output; PVR: pulmonary vascular resistance; Sv,O2: mixed venous oxygen saturation; #: n = 73 due to missing values; : n = 42 due to missing values.